Clinical trial
Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
NCT00332956 · DynPort Vaccine Company LLC, A GDIT Company, Industry · Completed
Key facts
| NCT number | NCT00332956 |
|---|---|
| Title | Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers |
| Official title | A Phase 2 (a), Dose-Blinded, Block-Randomized, Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers |
| Lead sponsor | DynPort Vaccine Company LLC, A GDIT Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Healthy Volunteers |
| Intervention type | Biological |
| Interventions | rFIV vaccine, rF1V vaccine, rF1V vaccine 160 mcg given on Study Days 0, 56, 182 |
| Enrollment | 400 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jun 2, 2006 |
| Last update posted | Dec 2, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: